Thumbnail Image
Item

CD44: A New Prognostic Marker in Colorectal Cancer?

Ziranu, Pina
; 
Pretta, Andrea
; 
Aimola, Valentina
; 
Cau, Flaviana
; 
Mariani, Stefano
; 
D'Agata, Alessandra Pia
; 
Codipietro, Claudia
; 
Rizzo, Daiana
; 
Dell'Utri, Veronica
; 
Sanna, Giorgia
... show 8 more
Citations
Altmetric:
Genre
Journal article
Date
2024-04-19
Advisor
Committee member
Group
Department
Biology
Subject
CD44
 Cancer stem cells
 Colorectal cancer
 Predictive marker
 Prognostic marker
 Target therapies
Permanent link to this record
https://scholarshare.temple.edu/handle/20.500.12613/11952
Collections
Faculty/Researcher Works
Show all metadata
Files
Thumbnail Image
Faa-JournalArticle-2024-04.pdf
Adobe PDF, 1.1 MB
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.3390/cancers16081569
Abstract
Cluster of differentiation 44 (CD44) is a non-kinase cell surface glycoprotein. It is overexpressed in several cell types, including cancer stem cells (CSCs). Cells overexpressing CD44 exhibit several CSC traits, such as self-renewal, epithelial–mesenchymal transition (EMT) capability, and resistance to chemo- and radiotherapy. The role of CD44 in maintaining stemness and the CSC function in tumor progression is accomplished by binding to its main ligand, hyaluronan (HA). The HA-CD44 complex activates several signaling pathways that lead to cell proliferation, adhesion, migration, and invasion. The CD44 gene regularly undergoes alternative splicing, resulting in the standard (CD44s) and variant (CD44v) isoforms. The different functional roles of CD44s and specific CD44v isoforms still need to be fully understood. The clinicopathological impact of CD44 and its isoforms in promoting tumorigenesis suggests that CD44 could be a molecular target for cancer therapy. Furthermore, the recent association observed between CD44 and KRAS-dependent carcinomas and the potential correlations between CD44 and tumor mutational burden (TMB) and microsatellite instability (MSI) open new research scenarios for developing new strategies in cancer treatment. This review summarises current research regarding the different CD44 isoform structures, their roles, and functions in supporting tumorigenesis and discusses its therapeutic implications.
Description
Citation
Ziranu, P.; Pretta, A.; Aimola, V.; Cau, F.; Mariani, S.; D’Agata, A.P.; Codipietro, C.; Rizzo, D.; Dell’Utri, V.; Sanna, G.; et al. CD44: A New Prognostic Marker in Colorectal Cancer? Cancers 2024, 16, 1569. https://doi.org/10.3390/cancers16081569
Citation to related work
MDPI
Has part
Cancers, Vol. 16, Iss. 8
ADA compliance
Embedded videos
License
Attribution CC BY
cb